Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RELATIVITY-073 in previously IO-naive advanced hepatocellular carcinoma after TKI progression
CTR20221168Phase 2Active
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of relatlimab, nivolumab in hepatocellular carcinoma (HCC), sponsored by Bristol Myers Squibb. Started Aug 2022; status: active.
02
Drugs
relatlimabnivolumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20221168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221168.